Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Propranolol for Treatment of Cocaine Addiction - 2

This study has been completed.
University of Pennsylvania
Information provided by:
National Institute on Drug Abuse (NIDA) Identifier:
First received: September 20, 1999
Last updated: February 3, 2010
Last verified: February 2010
The purpose of this study is to evaluate the safety and efficacy of propanolol in the early treatment of cocaine dependence.

Condition Intervention Phase
Cocaine-Related Disorders
Drug: Propranolol
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Propranolol for Treatment of Cocaine Addiction

Resource links provided by NLM:

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Side effects
  • Cocaine use
  • Cocaine withdrawal
  • Cocaine craving
  • Mood and anxiety
  • Clinical improvement

Estimated Enrollment: 0
Study Start Date: January 1987
Study Completion Date: January 2002
Primary Completion Date: January 2002 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   25 Years to 49 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Please contact site for information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000197

United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
University of Pennsylvania
Principal Investigator: Kyle Kampman, M.D. University of Pennsylvania
  More Information

Responsible Party: Kyle Kampman, University of Pennsylvania Identifier: NCT00000197     History of Changes
Other Study ID Numbers: NIDA-00238-2  K20DA000238 
Study First Received: September 20, 1999
Last Updated: February 3, 2010
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Anti-Arrhythmia Agents
Antihypertensive Agents
Vasodilator Agents processed this record on October 21, 2016